This book discusses in detail new aspects of the metabolic basis of important chronic liver diseases. Entities such as non-alcoholic fatty liver disease (fatty liver and Non-Alcoholic SteatoHepatitis -- NASH), diabeties in chronic hepetitis C, hemochromatosis, Wilson's disease, Gaucher disease, porphyria, as well as liver cirrhosis and its metabolic consequences will be discussed in detail. These clinical conditions are highly prevalent and affect millions of patients in the USA and world-wide. For example, non-alcoholic fatty liver disease is the most common cause of elevated liver enzymes in the general population. This field has been practically transformed over the last few years, with many new insights gained, regarding both pathogenesis and effective novel treatments.

In the first annual report on Alcohol and. Health to Congress (December, 1971), the then HEW Secretary Elliot L. Richardson called alcohol 'the most abused drug in the United States'. The report revealed that nine million Americans are alcohol abusers and that alcoholic individuals represent almost 10 % of the nation's work force. With spreading alcoholism, the incidence of physical damage due to alcohol has greatly increased. A question which is often raised is 'in which way does an alcoholic differ from a non-alcoholic?' Inquiries have focused on psychological make-up, behavioural differences and socioeconomic factors. More recently, however, physical differences have been delineated. Prior to the development of various disease entities, chronic ethanol exposure results in profound biochemical and morphological changes. Consequently an alcoholic does not respond normally to alcohol, or other drugs or even other toxic agents. Some of these persistent biochemical and morphological changes are the consequences of the injurious effects of ethanol, whereas others may represent the possible adaptive responses to the profound changes in intermediary metabolism which are a direct and im mediate consequence of the oxidation of ethanol itself. Differentiation between the effects of ethanol directly linked to its oxidation, and the adaptive and injurious effects of ethanol are not simple, and overlap is common. In general, however, metabolic effects are associated with the presence of relatively low ethanol concentrations, whereas injurious effects occur with high ethanol concentrations and/or after prolonged intake. High ethanol con centrations also produce so-called pharmacological effects.

Metabolic Fatty Liver Disease: Current Knowledge, Therapeutic Treatments, and Future Directions provides the most updated research findings and defines the current data gaps on metabolic fatty liver disease. The book extensively covers key areas in metabolic fatty liver disease research, including epidemiology (adults and children), economic burden, patient-reported outcome burden, natural history, current treatments, current diagnostic methods, controversies (NAFLD/MAFLD), current guidelines, fatty liver disease in the presence of other liver diseases as well as guidance on future research. This book will provide translational researchers with a current and comprehensive resource dedicated to all aspects of research in metabolic fatty liver disease, identify current gaps in research and make future research recommendations. It also offers clinicians a look at important background information in metabolic fatty liver disease and thoroughly reviews the latest research in this area to inform treatment outcomes. - Compiles the latest, up-to-date science from key experts in the field on metabolic fatty liver disease - Reviews best practices and current guidelines for a comprehensive overview - Identifies recommendations for future research endeavors

In this issue of Endocrinology and Metabolism Clinics of North America, guest editors Drs. Sherouk Fouda and Joseph M. Pappachan bring their considerable expertise to the topic of Metabolic Associated Fatty Liver Disease. Top experts address the various ways metabolic associated fatty liver disease is related to other conditions such as diabetes, sarcopenia, PCOS, and more, as well as the management of MAFLD and cardiovascular implications. - Contains 12 practice-oriented topics including obstructive sleep apnea and MAFLD; the interlink between MAFLD and polycystic ovary syndrome; pregnancy and MAFLD; MAFLD and gut microbiota; and more. - Provides in-depth clinical reviews of metabolic associated fatty liver disease, offering actionable insights for clinical practice. - Presents the latest information on this timely, focused topic under the leadership of experienced editors in the field. Authors synthesize and distill the latest research and practice guidelines to create clinically significant, topic-based reviews.

This book is a printed edition of the Special Issue "Non-Alcoholic Fatty Liver Disease Research 2016" that was published in IJMS

Alcohol abuse, alcohol intolerance, alcohol dependence and other alcohol-related disabilities are some of the most challenging public health problems facing our modern-day society. The purpose of this comprehensive monograph is to review the available knowledge concerning the pharmacogenetic basis of alcohol sensitivity and its physiolgical implications and to synthesize the bulk of existing knowledge regarding metabolic features and biomedical disturbances related to alcoholism. The chapters cover a broad array of disciplines including an overview of historical and epidemiological aspects, biochemistry and molecular genetics of enzymes involved in alcohol metabolism, biochemical and neuropsychopharmacological effects of alcohol. Major emphasis is placed on the role of genetic factors in alcoholism. The experimental details are summarized and a comprehensive bibliography is included.

Now fully revised and updated, Clinical Biochemistry, third edition is essential reading for specialty trainees, particularly those preparing for postgraduate examinations. It is also an invaluable current reference for all established practitioners, including both medical and scientist clinical biochemists. Building on the success of previous editions, this leading textbook primarily focuses on clinical aspects of the subject, giving detailed coverage of all conditions where clinical biochemistry is used in diagnosis and management - including nutritional disorders, diabetes, inherited metabolic disease, metabolic bone disease, renal calculi and dyslipidaemias. The acquisition and interpretation of clinical biochemical data are also discussed in detail. Expanded sections on haematology and immunology for clinical biochemists provide a thorough understanding of both laboratory and clinical aspects New chapters are included on important evolving areas such as the metabolic response to stress, forensic aspects of clinical biochemistry and data quality management An extended editorial team - including three expert new additions - ensures accuracy of information and relevance to current curricula and clinical practice A superb new accompanying electronic version provides an enhanced learning experience and rapid reference anytime, anywhere! Elsevier ExpertConsult.com Enhanced eBooks for medical professionals Compatible with PC, Mac®, most mobile devices and eReaders, browse, search, and interact with this title - online and offline. Redeem your PIN at expertconsult.com today! Straightforward navigation and search across all Elsevier titles Seamless, real-time integration between devices Adjustable text size and brightness Notes and highlights sharing with other users through social media Interactive content